Page 64 - CIBERES2016-ENG

leaD researcher
Martín Montañés, Carlos
Universidad de Zaragoza
Calle Pedro Cerbuna, 12 50009 Zaragoza
(+34) 976 761 759 [email protected] group website
GROUP MEMBERS
Staff members: Cebollada Solanas, Alberto | Lampreave Carrillo, Carlos
Associated members: Aguilo Anento, Ignacio | Ainsa Claver, José Antonio | Broset Blasco, Esther | Dias Rodrigues, Liliana Isabel | Gómez Aguirre, Ana Belén | Gómez Lus, Rafael | Gonzálo Asensio, Jesús | Gracia Díaz, Begoña | Ibarz Bosqued, Daniel | Iglesias Gozalo, María José | Lafoz Pueyo, Carmen | Lucía Quintana, Ainhoa | Otal Gil, Isabel | Pico Marco, Ana | Revillo Pinilla, María José | Rubio Calvo, María Carmen | Samper Blasco, Sofia Luisa | Vitoria Agreda, María Asunción
Main lines of research
Our Research Group on Mycobacterial Genetics has been working since 1992 in three lines of research funded by European and national research grants, being recognized as a leading group at the international level. Our current research interests are:
• Construction of New Vaccines against Tuberculosis, focusing on genes implicated in the pathogenicity and
virulence of M. tuberculosis. PI Carlos Martín.
• Molecular Epidemiology of Tuberculosis & Transposition and Latency of M. tuberculosis focusing on the
study of risk factors of transmission, and differences between strains of major epidemiological importance
and the mechanism of slow growth of the Koch bacillus.PI Sofía Samper.
• Molecular Bases of Drug Resistance in Mycobacteria, focusing on the contribution of efflux pumps to intrinsic
drug resistance and in the discovery of novel antituberculosis compounds. PI José Antonio Ainsa Altogether, our commitment is to study the complexity of M. tuberculosis by using a multidisciplinary approach and to work in coordination with other national and international research groups.
Active Projects:
Line 1: TBVAC H2020 643381 - H2020-PHC-2014 “Advancing novel and promising TB vaccine candidates from discovery to preclinical and early Clinical development” 2015-18 • BIO2014-52580-P “Innovando MTBVAC como vacuna contra la tuberculosis y nuevas aplicaciones terapéuticas en cáncer”. 2015-18. • INNPACTO: Ref. IPT-2012-
64
PROGRAMMES
Infectious Respiratory Diseases